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Abstract
Malaria  infection  during  pregnancy  is  an  important  public  health  problem  with
substantial risks to both the mother and foetus. Pregnant women are the most vulnerable
group  of  malaria‐associated  morbidity  and  mortality.  A  pregnant  woman  has  an
increased risk (up to four times) of getting malaria and twice the chances of dying from
malaria, compared to a non‐pregnant adult, becuase the immune system is partially
suppressed during pregnancy. Malaria in pregnancy not only affects the mother but also
has a dangerous sequel for the developing foetus, resulting in premature delivery or
intrauterine growth retardation. Diagnosis of malaria in pregnancy remains a challenge
due to the low parasite density and placental sequestration of Plasmodium falciparum.
Thus, there is an urgent need for new diagnostic methods to detect malarial parasites
in the pregnant women. Though antimalarial drugs are available, which can be safely
given in the pregnancy, increasing drug resistance of malarial parasite may pose a big
problem in the future. In this chapter, we review the burden of pregnancy‐associated
malaria  (PAM),  its  pathogenesis,  diagnostic  issues  during  pregnancy  and  recent
guidelines for chemoprophylaxsis and treatment.
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1. Introduction
Pregnancy‐associated malaria (PAM) is a major health problem, which not only affects mother
but also affects the developing foetus. Worldwide, 50 million women are at risk of PAM per
annum [1, 2]. Depending upon the transmission pattern of malaria, PAM has been studied in
two different geographical regions: one with a high and stable transmission rate (Africa) and
another one with a low and unstable transmission rate (Asia‐Pacific region). The majority of
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the studies are from Sub‐Saharan Africa, where Plasmodium falciparum causes the majority of
the cases. Approximately 25 million pregnant women are at risk of P. falciparum infection, and
25% women had evidence of placental infection at the time of delivery [3]. Due to the high
endemicity of malaria in these regions, adults develop natural immunity due to repeated
infections; thus, PAM rarely results in fever and remains undetected and untreated. On the
other hand, Asia‐Pacific region has a low transmission of P. falciparum and women have little
acquired immunity against malaria. In Asia‐Pacific region, most pregnant women are at a risk
of  Plasmodium vivax  infection.  Asia‐Pacific  region  consists  of  WHO South‐east  Asia  and
Western Pacific regions [3]. Approximately, 75 million women became pregnant in the Asia‐
Pacific region in 2007 [4]. Majority of these cases were from India and China. In low transmis‐
sion settings, malaria in pregnancy is associated with anaemia, an increased risk of severe
malaria and it may lead to spontaneous abortion, still birth, prematurity and low birth weight.
In such settings, all pregnant women are affected irrespective of the number of times they have
been pregnant. Infection with P. vivax, as well as with P. falciparum, leads to chronic anaemia
and placental infection, resulting in birth weight reduction and increased neonatal mortality.
However, reduction in birth weight in P. vivax is only two‐third as associated with P. falcipa‐
rum. Effect of P. vivax appears to increase with successive pregnancies [5].
One should be cautious while accessing the burden of malaria as there are many gap holes in
the knowledge of epidemiology and burden of malaria in pregnancy. Long‐term prospective
studies are required for accessing the true incidence of PAM. Study designs and methodology
should also be kept in mind while calculating the estimates of the burden of malaria [6–8].
Recently, verbal autopsy has been used in a study published in The Lancet [7], in which authors
have interviewed the relatives of a person who has recently died to determine a cause of death.
The results are astonishing in terms of numbers as there is a great disparity between malaria
death rates of Lancet group estimates and WHO estimates [8]. The Lancet study has projected
the estimates of 1.24 million deaths worldwide which includes 7,14,000 deaths under the age
of 5 as compared to WHO estimates of 6,55,000 deaths worldwide which includes 5,63,300
deaths under the age of 5 [8]. The reliability of these findings is a matter of debate, and there
is an urgent need to review these findings involving a broader group of experts, so that malaria
control programs can be reformulated with newer targets. In Africa with stable transmission,
the median prevalence of maternal malaria infection (defined as peripheral or placental
infection) in all gravidae has been estimated to be 27.8% [1, 9]. These are the minimum estimates
as they are based on single‐point prevalence and are based upon light microscopy, which
cannot detect the sub‐microscopic parasitemia of pregnancy. So, more studies are required
which can detect malaria with high sensitivity and specificity such as Plasmodium DNA
detection by polymerase chain reaction (PCR) and placental histology. In a low‐transmission
African setting, the median prevalence of peripheral and placental parasitemia has been
estimated to be 13.7 and 6.7% respectively [10]. However, outside Africa regions with low‐
transmission have respective estimates of 6.2 and 9.6% [10]. It has been estimated that placental
infection in regions of stable transmission in Africa are identified more frequently in dry
seasons as infection acquired during rainy season may persist for several months in placenta
[11, 12]. Thus, during the low‐transmission season also one can get the PAM with a higher
frequency.
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Although P. vivax has been known to be associated with malaria in pregnancy for the quite
long time, its impact has been accessed only recently [13]. Studies from India, Thailand and
Papua, Indonesia showed that low birth weight neonates and anaemia are more pronounced
as compared to non‐infected pregnant women, but severity was less as compared to P.
falciparum associated malaria in pregnancy [14–16].
2. Risk factors
2.1. Gravidity
Primigravidae are at increased risk of infection in high‐transmission areas, whereas they are
less marked in low‐transmission areas as women of all gravidities are susceptible to severe
maternal and foetal outcome. Thus, parity specific immunity plays an important role in PAM.
2.2. Maternal age
Younger age group is an independent risk factor for PAM. Thus, age‐specific immunity protects
an individual from PAM.
2.3. HIV infection
HIV increases the risk of acquiring malaria in pregnancy by weakening the immunity. It also
hampers the cytokine responses to malaria. These patients have decreased IL‐12 levels, which
in turn lead to decreased interferon‐γ leading to increased susceptibility to placental malaria
in HIV. Malaria increases HIV viral load in pregnancy and also increases the expression of
CCR5, which is an important co‐receptor for HIV cell entry. Malaria and HIV are linked in
other ways also, that is, The DARC gene which protects against vivax malaria might increase
susceptibility to HIV [8, 17].
2.4. Effect of Plasmodium species
All the four species of Plasmodium can infect pregnant women, but the prevalence and effect
of Plasmodium ovale and Plasmodium malariae in pregnancy are currently unknown. Plasmodium
knowlesi is the commonest cause of malaria in Malaysia, but it is relatively rare during
pregnancy [18]. Pregnant women are at increased risk to both P. vivax as well as P. falciparum
infection, but the risk is more for P. falciparum due to placental cytoadherence. Mixed infections
can also occur in pregnancy, but the prevalence of mixed infections decreases with increasing
age and gravidity. Differences in between P. vivax and P. falciparum are important for under‐
standing pathogenesis of malaria in pregnancy due to different species. P. vivax infects
reticulocytes after binding of merozoites with Duffy antigen receptor, which is lacking in
African population leading to protection against P. vivax [15]. This also helps in limiting the
parasitemia in P. vivax infections as compared to P. falciparum infections where mature RBCs
are invaded leading to relatively high parasitemia [11]. Infected RBCs with P. vivax do not
express erythrocyte surface proteins required for sequestration, which is well documented in
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P. falciparum infections [11, 19]. This heavy sequestration in placenta is discussed below that is
associated with high parasitemia in placenta leading to low birth weight neonates and
anaemia. Lastly, relapsing hypnozoite forms characteristics of P. vivax may complicate the
clinical course of infection. This suggests that systemic infection in mother is playing an
important role in pathogenesis of PAM due to P. vivax as compared from P. falciparum where
placenta is heavily infected by malaria parasite.
3. Pathogenesis
3.1. Placental changes associated with malaria
Infected erythrocytes tend to lodge in much higher densities in intervillous space as compared
to the peripheral circulation [20]. Due to sequestration of infected erythrocytes, trophozoites
and shizonts are absent in peripheral blood [21]. PAM is also associated with increased
numbers of phagocytic cells in the intervillous space along with the deposition of malarial
pigment (haemozoin). Precise and accurate diagnosis requires an examination of histological
sections of placenta. Based upon parasitized erythrocytes and haemozoin, placental changes
have been categorized into four classes (Table 1).
S. no.  Category  Description 
1.  Not infected  No evidence of parasitized erythrocytes or malarial pigment 
2.  Active‐acute  Parasitized erythrocytes present, with no or minimal pigment deposition in fibrin 
3.  Active‐chronic  Presence of parasitized erythrocytes along with substantial
amount of pigment in cells or in fibrin 
4.  Past  Absence of parasites but presence of pigment 
Table 1. Description of placental pathology in PAM (adapted from Ismail et al. [67]).
Recently, studies have shown that chronic infections are associated with lower maternal
haemoglobin and low birth weight due to foetal growth retardation, whereas preterm births
are more closely associated with acute infection having high parasitemia.
3.2. PAM is not always associated with pathology
It has been seen that microscopic examination of blood smears is not a sufficient diagnostic
tool to detect the sub‐microscopic infections. These are mainly detected by polymerase chain
reaction, and a study by Mankhambo et al. [22] has shown that sub‐microscopic infections are
not associated with low birth weight or with lower maternal haemoglobin. Thus, it is the
density of the parasites which matters a lot and women might not suffer from adverse effect
of PAM, in whom density of the parasites is under control. Therefore, PAM is common but is
not always associated with adverse outcomes.
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3.3. Plasmodium infected erythrocytes that cause malaria in pregnant versus non‐
pregnant women
Placental‐infected erythrocytes with P. falciparum differ in a number of ways as compared to
infected erythrocytes from non‐pregnant women (Figure 1) [19]. Placental‐infected erythro‐
cytes adhere to glycosaminoglycan receptors throughout the intervillous space [23, 24].
Chondroitin sulphate A has been considered to be the most predominant receptor placental
adhesion receptor, which is present as a glycosaminoglycan side chain [25] of tissue throm‐
bomodulin [26] and also as a part of secreted low‐sulphated aggrecan in intervillous space. In
contrast, infected erythrocytes of non‐pregnant women do not use this receptor, and seques‐
tration occurs near to vascular wall in other tissues. Another important difference is that
rosettes formation does not occur among placental infected erythrocytes, which is a common
feature of infected erythrocytes of non‐pregnant women [27, 28]. Placental erythrocytes can
adsorb IgM [29], and the adhesion ligands vary in their sensitivity to trypsin digestion [30].
On the other hand, infected erythrocytes of non‐pregnant women can adsorb IgM on their
surface. Thus, parasite antigens causing adhesion of infected erythrocytes to chondroitin
sulphate A are different from those antigens that are expressed on infected erythrocytes during
non‐placental P. falciparum infections. All these surface expressed antigens are collectively
known as variant surface antigens (VSAs).
Figure 1. Comparison of malaria‐infected erythrocytes in pregnant women (a) versus non‐pregnant individuals (b). In
pregnant women, infected erythrocytes adhere to chondroitin sulphate A receptor present in intervillous area of pla‐
centa, whereas in non‐pregnant women infected erythrocytes adhere to CD36 or ICAM1 and also exhibit rosette forma‐
tion and agglutination [19].
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3.4. Humoral immune response to variant surface antigens in pregnancy
VSAs are the main targets of IgG which provides the protective immunity in response to
repeated episodes of P. falciparum infections in non‐pregnant individuals. Thus, if VSA is
different among pregnant and non‐pregnant individuals, then susceptibility to infection with
P. falciparum in previously clinically immune women when they become pregnant could easily
be explained. This would also explain the increased chances of PAM in women of low gravidity
in areas with high transmission. A study by Fried et al. [31] has provided an evidence which
shows that VSA expressed by placental infected erythrocytes are immunologically distinct.
They have shown that IgG derived from multigravidae who were exposed to P. falciparum,
inhibit the adhesion of infected erythrocytes to chondroitin sulphate A that are obtained from
primigravidae [32]. Whereas, adhesion of infected erythrocytes to chondroitin sulphate A is
not inhibited by serum from either primigravidae or men. IgG1 is known to be the predominant
subclass of IgG against VSA in PAM [33, 34].
3.5. Humoral immune response to other antigens in pregnancy
Humoral immune response to other blood stage antigens have also been known to provide
immunity in PAM. Thus, young age is an independent risk factor for PAM. The relative
protection from severe malaria has also been observed in the area of high exposure to malaria
prior to pregnancy. However, humoral immune response to pre‐erythrocytic antigens/blood
stage antigens other than VSA is not sufficient to provide adequate immunity in PAM [32].
3.6. Protective antibodies in PAM
There is an inverse relationship between gravidity and PAM. Protective levels of antibodies
against VSA inhibiting adhesion to chondroitin sulphate A have an inverse relationship to low
birth weight, preterm delivery and low maternal haemoglobin levels [35, 36]. More studies are
required to identify the other targets of protective immune response in pregnancy.
3.7. Increase in monocyte infiltrates in placental intervillous space
Maternal mononuclear cells are stimulated by sequestrated infected erythrocytes in placenta.
Activated mononuclear cells secrete β‐chemokines that are chemotactic for macrophages and
monocytes. Macrophage migration‐inhibitory protein (MIF) helps in retention and activation
of macrophages [37, 38]. Thus, induction of these cytokines helps in increase of monocytes and
macrophages in the intervillous space in PAM. These cells also act as antigen presenting cells
to T cells [39].
3.8. Placental cytokines in PAM
During normal pregnancy, cytokine balance is shifted towards Th2‐type immune response
[40], and Th1‐type immune response is associated with adverse maternal and foetal outcomes
such as maternal anaemia, spontaneous abortions and premature deliveries. The Th1‐type of
immune response aids in clearing the parasites from the placenta. The various mechanisms
documented include increase in phagocytic activity of macrophages and increase in nitric
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oxide activity. In addition to that, oxygen‐free radicals along with stimulation and proliferation
of T‐cells also play an important role in clearing the parasites. Thus, Th1‐type immune response
helps in fighting against the malaria infection, but its overproduction is harmful as it can
terminate the pregnancy. The ill effects of pro‐inflammatory cytokines are counterbalanced by
IL‐10 and have been shown to be up‐regulated in intervillous space. Thus, it is the delicate
balance between Th1 and Th2 immune response which provides immunity in PAM.
3.9. Role of innate cells in PAM
Macrophages, dendritic cells, natural killer (NK) cells, γδ T cells are the arms of innate immune
response, which helps in shaping the adaptive immune response to malaria. They help in early
production of cytokines which determine the response to infection by modulating the immune
response. Placental macrophages help in eliminating the parasites. Infected erythrocytes also
adhere to NK cells to produce interferon‐γ. Adherence to dendritic cells is mediated by CD36
which further helps in antigen presentation to T cells [41, 42]. NK T cells have been shown to
be protective against blood‐stage malaria infections in athymic mice. Toll‐like receptors (TLRs)
help in recognition of asexual‐stage of P. falciparum by innate cells. Polymorphism in TLR 4
and TLR 9 is known to be associated with low birth weight, foetal growth retardation and
maternal anaemia [43, 44]. There are few studies available which confirm the specific roles of
innate immune response in PAM, so more studies are required to unveil the role of innate
immune response in PAM among humans.
3.10. T and B cell response in PAM
During pregnancy, very delicate immunological balance is maintained so that mother's
immune system must remain tolerant to the developing foetus but provide protection against
invading pathogens on another side. Earlier studies have shown that pregnancy predisposes
the women to severe disease due to the suppression of cell‐mediated immune response [45].
However, these days submicroscopic parasitemia is well documented in which slides for
peripheral smear are negative, but PCR is positive. It has been postulated that decrease in T‐
cell proliferative responses might be caused by the absence of memory T cells due to seques‐
tration as compared to earlier concept of immunosupression [46].
Fievet et al. [47] investigated the immune response to P. falciparum antigen in Cameroonian
primigravidae, evolution after delivery and during the second pregnancy. They have shown
that levels of antibodies to Pf155/RESA are lower during the pregnancy in comparison to levels
of antibodies after the delivery. However, levels of P. falciparum asexual blood stages are higher
during the pregnancy than after delivery. This increase during pregnancy has remained
unexplained and has not been reported earlier. It has been proposed that due haemodilution
and passive transfer of IgG to developing foetus, there occurs a decrease in maternal IgG levels
during pregnancy. It has also been postulated that immunosuppressionwhich occurs during
pregnancy may impair the T‐cell subsets differentially leading to impairment of IL‐2 cellular
response,but proliferative responses, IL‐4, IFN‐γ responses are either not affected or moder‐
ately increased. This suppression of IL‐2 has been linked to the hypothesis supporting the
transient depression of Th1 immune response during pregnancy. However, the suppression
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of IL‐2 is not parallel with the reduction of IFN‐γ, suggesting Th1 subset might be differential
affected by the PAM [48, 49]. Fievet et al. [49] have shown that cellular immune response is
related to previous placental infection and parity even after the pregnancy in relation to P.
falciparum infections. They have shown that T‐cell proliferative responses and cytokine
production (IL‐2, IL‐4, IL‐10 and IFN‐γ) is significantly higher in multigravidae as compared
to primigravidae when cells are stimulated with chondroitin sulphate A‐adhering RP5
strains of P. falciparum but not with other strains which lack adherence to chondroitin sulphate
A. These findings will be useful in designing the vaccine for malaria in pregnancy, if parity‐
dependent stimulation of cytokine production is important in PAM. In PAM, high levels of
IgGspecific against VSA has been documented along with higher number of VSA‐specific
memory B‐cells. Surface‐exposed epitopes of VAR2CSA are the main target of antibody
production [49].
Figure 2. Probable mechanisms by which pregnancy‐associated malaria can cause preterm delivery or foetal growth
retardation [19].
3.11. Pathogenesis of foetal growth retardation in malaria
Foetal growth retardation is known to be associated with chronic malaria. Whether it occurs
due to mainly due to events occurring near the delivery (e.g. cytokines, impaired uteropla‐
cental blood flow or biochemical imbalance in the placenta) or due to chronic infection which
slowly compromise the foetal growth, are still unknown. Malaria is known to impair uterine
spiral arteries remodelling during trophoblast invasion, leading to decreased placental
circulation [50]. Mechanical obstruction of intervillous space by infected erythrocytes,
monocytes and deposition of fibrin are also known to compromise the placental circulation
[51]. Cytokines released by monocytes could directly or indirectly affect nutrient transport
mechanisms. Thus, decreased blood flow, impaired placental development and impaired
nutrient transport are the probable mechanisms by which foetal growth retardation occurs
(Figure 2).
Current Topics in Malaria60
3.12. Pathogenesis of preterm delivery due to malaria
Preterm birth occurs delivery before 37 weeks of gestation, and it is known to be closely
associated with high parasitemia, maternal anaemia, increased levels IL‐10 and TNF‐α [38].
But how it occurs is still unknown.
3.13. Pathogenesis of anaemia in malaria
Anaemia in malaria is a multifactorial, caused by a combination of erythrocyte destruction
(both infected and uninfected erythrocytes) and bone marrow dysfunction. Other associated
factors such as hookworm infection, HIV infection, chronic inflammation, iron and folic acid
deficiency, accumulation of pigmented monocytes and their inflammatory mediators are
known to suppress the erythropoesis [52, 53].
4. Role of hormones in PAM
Malaria in pregnancy has been associated with an increase in cortisol levels, which may reflect
a stress response to malaria. It has also been postulated to suppress the immune system, but
exact mechanism how it occurs is still a matter of debate. In late pregnancy, it is also associated
with reduced oestradiol levels [54, 55].
5. Maternal outcomes in malaria
The maternal outcome in malaria depends upon the degree of immunity acquired by the
pregnant women. Thus, epidemiological transmission has an important effect on maternal
outcome. In areas of high transmission, only few individuals get the clinical signs and
symptoms of malaria and same applies to pregnant women [10]. In Africa, malaria is re‐
sponsible for approximately 26% of severe anaemia cases among pregnant women of all
gravidities [2]. Hospital‐based studies have shown that malaria‐related maternal mortality
rate among pregnant women, varies from 0.5 to 23.0%, whereas it varies from 2.9 to 17.6%
among community‐based studies [56]. However, in areas having low, unstable and seasonal
transmission, women are more susceptible to develop the severe disease. In India, malaria‐
related maternal mortality rate among pregnant women varies from 7.0 to 66.6%, and in
Thailand it varies from 10 to 27% [57]. Targeted treatment approach is required to curtail
these figures of mortality.
6. Child outcomes in malaria
Malaria has the devastating effects on the developing foetus resulting in various outcomes
(Figure 3). Low birth weight is an independent risk factor for the increase in infant mortality
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rate [12, 58]. Risk of low birth weight doubles in primigravidae having placental malaria.
Malaria in pregnancy is responsible for 20% of low birth weight deliveries in Sub‐Saharan
Africa [9]. In areas of high transmission, women have good‐level immunity acquired due to
repeated infections, thus decreasing the episodes of febrile illness, an important predisposing
factor which causes preterm delivery. Furthermore, it is the intrauterine growth retardation
which is the major cause of low birth weight babies as compared to areas having low rates of
unstable transmission where preterm delivery is likely to be a more important cause of low
birth weight due to poor levels of acquired immunity [10]. Malaria in pregnancy is also
responsible for increased neonatal deaths, stillbirths, spontaneous abortions and anaemia.
Steketee et al. [1] have reviewed the similar factors in Sub‐Saharan Africa and estimated low
birth weight, preterm delivery and stillbirth attributable to malaria in pregnancy, to vary from
8 to 14%, 8 to 36% and 13 to 70% respectively.
Figure 3. Maternal and child outcomes associated with malaria in pregnancy [10].
Placental malaria is also known to reduce the maternal antibodies to the foetus resulting in
other infections such as measles and Streptococcus pneumonia [59, 60]. Recent studies have
reported a rise in congenital malaria whose prevalence varies from 8 to 33% [61–63]. The
increase may attributed to increase in drug resistance, HIV, increase in virulence and increased
detection rates. Data is lacking which can provide direct evidence of malaria in pregnancy
affecting development of the child in the long term. However, study from Malawi [64] has
shown that placental malaria is an independent risk factor for anthropometric status in infancy.
Other risk factors such low birth weight, anaemia can hamper the development of the brain
and may result in cognitive disorders.
7. Diagnosis of PAM
Diagnosis of malaria in pregnancy is challenging as P. falciparum parasites are either absent or
undetectable in peripheral blood, due to the sequestration of parasites in placenta [65]. This is
due to the fact that infected erythrocytes are sequestered in the intervillous space [23].
Infections having a low parasite density may also affect the pregnant women and her devel‐
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oping foetus [66]. Thus, early diagnosis is essential for the timely initiation of treatment.
Although, it is considered to be a gold standard for histological examination of the placental
malaria, it is not applicable for routine diagnosis [67, 68]. However, placental examination is
not possible before the delivery and thus, antenatal placental infection can only be inferred by
peripheral blood smear examination.Although polymerase chain reaction (PCR) has the
potential to diagnose malaria in pregnancy with higher sensitivity and specificity. A recent
study by Mayor et al. [69] have shown that among the PCR positive for P. falciparum in
peripheral and/or placental blood samples, 71.3, 61.5, 60.7 and 58.2% were negative by
peripheral microscopy, by HRP2 ELISA in plasma, by HRP2 RDT in plasma and by histology
respectively. However, molecular techniques are costly and are not available everywhere.
Studies [70, 71] have shown a marked underestimation of malaria infection in pregnant women
when diagnosed by standard microscopy in peripheral and placental blood as compared to
molecular techniques such as polymerase chain reaction (PCR). Thus, there is an urgent need
for more accurate diagnostic tools to detect malaria in pregnancy to prevent the negative
clinical impact of hidden infection in pregnancy.
8. Prevention and management of PAM
Prevention of PAM is an important public health issue. Mainly, three‐pronged approach has
been advised for reducing the burden of PAM which are as follows [72]:
1. Effective case management
2. ITNs: use of insecticide‐treated nets (ITNs)
3. IPT: intermittent preventive therapy in areas of stable transmission
In areas with low or unstable transmission of malaria, PAM can be controlled by timely
diagnosis, and treatment of acute cases as IPT will be not very useful as it is in high
transmission areas. Malaria in non‐immune pregnant women are prone to severe disease,
thus early initiation of antimalarials along with supportive management is very useful.
Use of ITNs is useful in high transmission areas as its use will decrease the exposure to
infective mosquito bites, thus decreasing the risk of placental malaria, low birth weight,
still births and furthermore, continue to protect the newborn baby during infancy, since
most babies sleep with their mothers [73]. However little is known about their effect in
decreasing the clinical malaria and low birth weight in low transmission areas [74].
PAM in high transmission areas may be associated with placental parasitemia, causing
maternal anaemia even in the absence of documented peripheral parasitemia. Therefore,
it is recommended to treat presumptively whenever pregnant women present with severe
anaemia, whether or not she has a history of fever and whether or not peripheral parasi‐
temia is present [75, 76]. It is also recommended to give iron and folic acid supplementation
to all pregnant women as a part of routine antenatal care. A study from Western Kenya
has shown a dramatic reduction of 38% in the incidence of malaria parasitemia, 47%
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reduction in anaemia and 28% reduction in the prevalence of low birth weight babies in
those pregnant women who regularly used ITNs [77].
IPT has replaced the previous policy of chloroquine chemoprophylaxsis given weekly
[78], as it was associated with poor patient compliance and increased chances of devel‐
oping drug resistance [79]. Curative treatment dose of effective anti‐malarial drug is given
at predefined intervals during the course of pregnancy. As shown in Figure 4, all women
should receive at least two doses of IPR in the second and third trimesters of pregnancy
with the aim of clearing the placenta from parasites at the time of rapid foetal growth [80].
Though a single dose is also beneficial,yet one should aim for giving 2–3 doses. Sulpha‐
doxine‐pyrimethamine (SP) is the most common drug used in IPT, due to its long half‐life
and good safety profile in pregnancy [75, 81]. However, SP resistance in P. falciparum is
prevalent throughout the Sub‐Saharan Africa. The Queen Elizabeth Central Hospital
Epidemiology of Resistance in Pregnancy‐Associated Malaria (QuEERPAM) study [82]
has shown promising results regarding the antenatal use SP and concluded that it does
not exacerbate PAM despite the expansion of drug‐resistance P. falciparum. Thus, in areas
with substantial resistance, SP can be used as a component of antenatal care because
pharmacologically, SP in the presence of partial host immunity can clear the resistant
parasites, with limited placental inflammation. Thus, artemisinin‐based combination
therapy in IPT must now be evaluated along with priority‐based research on evaluating
the effectiveness and safety profile of newer antimalarial drugs [83, 84]. Recently, artemi‐
sinin‐based chemotherapy has been found to be safe for the treatment of P. falciparum‐
associated malaria in pregnant females during first trimester. In near future, quinine‐
based antimalarial therapy during first trimester might be replaced by artemisinin
combination therapy due to the encouraging results shown by Moore et al. [85].
Figure 4. Intermittent preventive treatment (IPT) dosing schedule as recommended by World Health Organization. All
women should receive at least two doses of IPT after quickening, as it helps in clearing the parasites at the time of
rapid foetal growth. IPT may also be given at fourth visit, if not received the requisite number of doses. Maximum
benefit is derived from 2 to 3 doses.
9. Conclusion
Malaria in pregnancy is an important public health problem. It not only affects mother but
also hampers the growth of developing foetus. In areas with high transmission rate of ma‐
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laria, population is relatively immune and patients do not present with symptomatic ma‐
laria, which delay the diagnostic workup. Moreover, predominant Plasmodium species in
such areas is P. falciparum that is known to cause sequestration of infected RBCs in placenta
leading to compromise in normal physiology of placenta. In areas of low‐transmission area,
P. vivax is the predominant species causing malaria in pregnancy. It mainly causes systemic
ill effects as compared to P. falciparum infection. Moreover, relapse of malaria could occur
due to hypnozoites that could further complicate P. vivax infection in pregnancy. The varia‐
tion in Plasmodium species among these two regions is mainly attributed to lack of Duffy‐
binding proteins that are absent among majority of African population making them
resistance to P. vivax infection as this protein is required by the parasite to invade reticulo‐
cytes.
Diagnosis is established by microscopic examination of peripheral blood smear and by rapid
antigen detection kit. However, parasitemia is difficult to establish by microscopy due to
sequestration of infected malarial parasite in placenta. Thus, molecular techniques such as
PCR, real‐time PCR are promising tools that can be utilized in future. Major disadvantage of
molecular techniques is that these are costly and require sophisticated laboratory equipment.
However, loop‐mediated isothermal amplification (LAMP) could provide an answer to such
a problem as it can be performed in simple water bath and does not require gel‐documentation
system as amplified products can be visualized by naked eye.
As majority of pregnant females suffering from malaria are asymptomatic, intermittent
preventive chemotherapy is advocated in high transmission areas. However, due to increase
in emergence of drug resistance, safety and efficacy of artemisinin‐based combination therapy
and newer antimalarials should also be established in near future along with implementation
of other vector control measures. Research is also required to develop new antimalarials, which
are safe in pregnancy for the radical cure of P. vivax infection.
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